Questran 4g/Sachet Powder For Oral Suspension

Description

Formulation: Powder for Oral Suspension
Strength: 4g per sachet

Description:
Questran (cholestyramine) is a medication used primarily for managing high cholesterol.
Questran 4g/Sachet Powder price.

levels and certain types of diarrhea. It works by binding to bile acids in the intestines, preventing their reabsorption and reducing the amount of cholesterol in the bloodstream. The active ingredient in Questran is cholestyramine, which is a bile acid sequestrant.

Questran 4g/Sachet in karachi.

Questran 4g/Sachet Powder For Oral Suspension.

Questran comes in the form of a powder that is mixed with water to form a suspension.

Questran 4g/Sachet in pakistan.

The powder is typically packaged in individual 4g sachets, making it easy to measure and administer. This form allows for flexible dosing depending on the patient’s condition.

Questran 4g/Sachet Powder For Oral Suspension in karachi.

Uses:

Hyperlipidemia (High Cholesterol): Questran helps to lower levels of low-density lipoprotein (LDL) cholesterol by binding bile acids in the intestine.
Bile Acid Diarrhea: It can be used to treat diarrhea caused by excess bile acids in the gastrointestinal tract.
Pruritus Associated with Biliary Obstruction: Questran is also used to alleviate itching caused by liver disease or bile duct obstruction.
Mechanism of Action:
Cholestyramine binds bile acids in the intestines, which are then excreted rather than being reabsorbed into the bloodstream. This helps to lower cholesterol levels and prevent diarrhea caused by bile acid malabsorption.

Questran 4g/Sachet Powder For Oral Suspension in pakistan.

Dosage:

Typically, the recommended dose starts at 4g per day.
The dose may be gradually increased based on the patient’s condition and response to the treatment.
Questran should be taken mixed with water or non-carbonated beverages for ease of consumption.
Key Points:

Questran 4gSachet.

Active Ingredient: Cholestyramine
Strength: 4g per sachet
Form: Powder for Oral Suspension
Administration: Oral, mixed with water or non-carbonated drinks
Uses: High cholesterol, bile acid diarrhea, pruritus from biliary obstruction
Precautions: Can interact with certain medications, and should be taken at least 1 hour before or 4-6 hours after other medications.
Side Effects:
Common side effects include constipation, abdominal discomfort, and bloating. In rare cases, it can lead to more severe gastrointestinal issues.

Storage:
Store in a cool, dry place away from direct sunlight. Keep out of the reach of children.

Acacia, citric acid, D&C Yellow No. 10 and FD&C Yellow No. 6, orange flavour (natural and artificial), polysorbate 80, propylene glycol alginate, and sucrose are among the inactive ingredients found in QUESTRAN powder. Aspartame, citric acid, colloidal silicon dioxide, D&C Yellow No. 10, FD&C Red No. 40, natural and artificial orange flavour, maltodextrin, propylene glycol alginate, and xanthan gum are among the inactive ingredients found in QUESTRAN LIGHT.

Clinical Pharmacology and Actions
The only likely precursor to bile acids is cholesterol. Bile acids are released into the intestines during regular digestion. The enterohepatic circulation returns a significant amount of the bile acids to the liver after being absorbed from the intestinal tract. Normal serum contains only trace amounts of bile acids.

Bile acids are adsorbent and combine with queston resin.

Arteriography has been used to evaluate the impact of severe lipid-lowering treatment on coronary atherosclerosis in hyperlipidemic patients.

Patients were treated for two to four years in these randomised, controlled clinical trials using either intensive combination therapy with diet plus colestipol (an anion exchange resin that works similarly to QUESTRAN and QUESTRAN LIGHT in terms of its mechanism of action and

effect on serum lipids) plus either nicotinic acid or lovastatin, or conventional measures (diet, placebo, or in some cases low dose resin). In patients with or at risk for coronary artery disease, intensive lipid-lowering combination therapy dramatically decreased the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions when compared to standard measures.